Anti-CD24 CAR-T was injected into pancreatic cancer tumours by tail vein injection or directly into pancreatic cancer tumours accompanied by intraperitoneal IL-2 injections twice a day for ten days by Amit Maliar et al. The results showed good performance of anti-CD24 CAR-T against tumours. This evidence concerns the gene CD24 and neoplasm.